Dalgety Ltd & Curaleaf Laboratories: Building the Future of Pharmaceutical-Grade Medical Cannabis in the UK
As the UK medical cannabis industry matures, the demand for reliable, pharmaceutical-grade, domestically produced cannabis medicines continues to grow. Through a strategic partnership with Curaleaf Laboratories, Dalgety Ltd is helping establish a new benchmark for quality, consistency, and supply chain integrity within the UK medical cannabis market.
This collaboration combines Dalgety’s cutting-edge EU-GMP cultivation infrastructure with Curaleaf Laboratories’ pharmaceutical manufacturing and distribution expertise, creating one of the most advanced fully integrated UK medical cannabis supply pathways available today.
What Sets Dalgety Apart From Other Medical Cannabis Producers?
Dalgety Ltd has emerged as one of the UK’s most technologically advanced and highly regulated medical cannabis operators. Unlike many companies reliant on imported flower or outsourced cultivation, Dalgety controls the entire cultivation and production process within the UK under strict EU-GMP pharmaceutical standards.
The company was the first in the UK to secure licences for the cultivation, manufacture, and supply of EU-GMP medical cannabis flower from a single domestic facility, a significant milestone for the British cannabis industry.
A State-of-the-Art Pharmaceutical Cultivation Facility
Dalgety’s advanced indoor cultivation facility spans over 30,000 square feet and has been purpose-built specifically for pharmaceutical cannabis production. Designed in collaboration with medical production specialists, the facility combines horticultural expertise with highly controlled environmental systems to ensure consistency at every stage of cultivation.
Key operational features include:
• Fully indoor pharmaceutical-grade cultivation
• AI-controlled environmental management systems
• Precision hydroponic cultivation techniques
• Automated lighting, irrigation, humidity, and temperature control
• Computer-managed climate stabilisation systems
• Full batch traceability from propagation to final product
• EU-GMP-compliant post-harvest processing and quality control
• Advanced air filtration systems comparable to operating theatre standards
• Extensive microbial and cannabinoid testing protocols
This infrastructure allows Dalgety to achieve exceptionally stable cannabinoid profiles and product consistency, a critical requirement for prescribing clinicians and patients alike.
Precision Cultivation Built for Medical Consistency
One of the major challenges within the global medical cannabis industry is maintaining consistency between batches. Dalgety addresses this through highly controlled cultivation methodologies designed specifically for pharmaceutical applications.
Unlike traditional cultivation environments, Dalgety’s facility utilises precision hydroponic growing systems and AI-assisted environmental monitoring to optimise every variable affecting plant development.
Each crop is cultivated under tightly regulated conditions, allowing Dalgety to maintain:
• Consistent THC and CBD ratios
• Uniform terpene profiles
• Pharmaceutical-grade microbial safety
• Repeatable product quality between harvests
• Stable cannabinoid expression for patient reliability
The cultivation process is overseen by specialist horticultural and biochemistry experts, including professionals with experience in large-scale international medical cannabis operations.
End-to-End UK Supply Chain Integration
A major differentiator for Dalgety is its vertically integrated UK production model.
Through its partnership with Curaleaf Laboratories, Dalgety’s UK-grown cannabis flower is manufactured and distributed through an entirely domestic pharmaceutical supply chain. This reduces dependency on overseas imports while significantly improving supply chain resilience and patient access.
The partnership delivers several critical benefits:
Faster Product Availability
Domestic production and manufacturing reduce delays associated with international importation and customs processes.
Greater Supply Chain Stability
A UK-based cultivation and distribution pathway helps minimise stock shortages and interruptions to patient treatment plans.
Improved Quality Assurance
By maintaining oversight from cultivation through to manufacturing and distribution, both Dalgety and Curaleaf Laboratories can ensure pharmaceutical consistency throughout the entire supply chain.
Enhanced Transparency for Healthcare Professionals
The ability to trace products from seed to patient provides clinicians with greater confidence in prescribing EU-GMP medical cannabis products.
Pharmaceutical-Grade Standards at Every Stage
Dalgety operates under rigorous EU-GMP standards and has undergone extensive regulatory validation processes involving both the MHRA and Home Office.
Its operational model incorporates:
• Pharmaceutical-grade cultivation protocols
• Continuous environmental monitoring
• Rigorous microbial testing
• Stability and cannabinoid validation procedures
• Controlled drying and curing methodologies
• Comprehensive quality assurance systems
• Secure, fully monitored facilities
This level of pharmaceutical oversight distinguishes Dalgety from many traditional cannabis cultivation models and positions the company closer to pharmaceutical manufacturing standards than conventional agricultural production.
Innovation Through Science and Technology
Dalgety’s approach is rooted in scientific precision rather than large-scale commodity cultivation.
The company has invested heavily in:
• Controlled-environment agriculture
• Advanced hydroponic systems
• AI-driven cultivation analytics
• Environmental optimisation technology
• Pharmaceutical compliance infrastructure
• Genetics selection and phenotype stabilisation
• Product consistency research
This focus on innovation supports the production of high-quality cannabinoid medicines designed to meet the expectations of clinicians, pharmacies, and regulators.
Driving Education and Transparency Within the UK Medical Cannabis Sector
In addition to its advanced cultivation and pharmaceutical operations, Dalgety Ltd has become increasingly recognised for its commitment to industry education and professional transparency.
As part of this commitment, Dalgety regularly opens the doors of its UK cultivation facility to healthcare professionals, clinicians, pharmacists, researchers, and industry stakeholders, offering a rare opportunity to see pharmaceutical cannabis cultivation firsthand within the UK.
Historically, much of the medical cannabis supplied to UK patients has been cultivated overseas, limiting opportunities for UK healthcare professionals to fully understand the cultivation, quality control, and production processes behind the medicines they prescribe. By providing direct access to its domestic cultivation and processing operations, Dalgety is helping bridge this knowledge gap and improve confidence within the healthcare community.
These educational facility visits allow healthcare professionals to gain deeper insight into:
- Pharmaceutical cannabis cultivation standards
- EU-GMP compliance procedures
- Controlled-environment cultivation systems
- Quality assurance and microbial testing processes
- Product consistency and batch control
- Post-harvest handling and processing methodologies
- UK regulatory and manufacturing frameworks
This open and collaborative approach reflects Dalgety’s wider commitment to transparency, scientific engagement, and advancing understanding of cannabis-based medicines within mainstream healthcare.
By creating opportunities for direct education and engagement, Dalgety is helping support informed prescribing, greater professional confidence and the long-term development of a trusted UK medical cannabis ecosystem.
Supporting the Long-Term Growth of the UK Medical Cannabis Industry
Dalgety and Curaleaf Laboratories share a common commitment to developing a sustainable, trusted, and patient-focused UK medical cannabis ecosystem.
Together, the partnership aims to:
- Expand access to UK-grown medical cannabis
- Improve long-term supply chain reliability
- Increase confidence among healthcare professionals
- Support regulatory best practice
- Deliver pharmaceutical-grade cannabinoid medicines
- Advance mainstream acceptance of cannabis-based treatments
As patient demand continues to increase across the UK, partnerships built on transparency, compliance and scientific integrity will play a critical role in shaping the future of cannabis medicine.